TW202220649A - 三叉神經痛之治療方法 - Google Patents

三叉神經痛之治療方法 Download PDF

Info

Publication number
TW202220649A
TW202220649A TW110128158A TW110128158A TW202220649A TW 202220649 A TW202220649 A TW 202220649A TW 110128158 A TW110128158 A TW 110128158A TW 110128158 A TW110128158 A TW 110128158A TW 202220649 A TW202220649 A TW 202220649A
Authority
TW
Taiwan
Prior art keywords
composition
compound
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TW110128158A
Other languages
English (en)
Chinese (zh)
Inventor
喬治 加里鮑迪
Original Assignee
瑞士商諾埃瑪製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾埃瑪製藥公司 filed Critical 瑞士商諾埃瑪製藥公司
Publication of TW202220649A publication Critical patent/TW202220649A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
TW110128158A 2020-07-30 2021-07-30 三叉神經痛之治療方法 TW202220649A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063058630P 2020-07-30 2020-07-30
US63/058,630 2020-07-30

Publications (1)

Publication Number Publication Date
TW202220649A true TW202220649A (zh) 2022-06-01

Family

ID=77520687

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110128158A TW202220649A (zh) 2020-07-30 2021-07-30 三叉神經痛之治療方法

Country Status (15)

Country Link
US (2) US20230172922A1 (https=)
EP (1) EP4188370A1 (https=)
JP (1) JP2023540849A (https=)
KR (1) KR20230047132A (https=)
CN (1) CN115989024A (https=)
AR (1) AR123108A1 (https=)
AU (1) AU2021316675A1 (https=)
BR (1) BR112023001621A2 (https=)
CA (1) CA3182457A1 (https=)
CL (1) CL2023000261A1 (https=)
IL (1) IL300124A (https=)
MX (1) MX2023001288A (https=)
PH (1) PH12023550204A1 (https=)
TW (1) TW202220649A (https=)
WO (1) WO2022023519A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
WO2011035209A1 (en) * 2009-09-17 2011-03-24 Vanderbilt Universtiy Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same

Also Published As

Publication number Publication date
EP4188370A1 (en) 2023-06-07
CN115989024A (zh) 2023-04-18
AU2021316675A1 (en) 2023-01-19
CL2023000261A1 (es) 2023-09-08
AR123108A1 (es) 2022-10-26
US20230172922A1 (en) 2023-06-08
WO2022023519A1 (en) 2022-02-03
MX2023001288A (es) 2023-04-28
CA3182457A1 (en) 2022-02-03
IL300124A (en) 2023-03-01
PH12023550204A1 (en) 2024-06-24
US20250345320A1 (en) 2025-11-13
BR112023001621A2 (pt) 2023-04-04
KR20230047132A (ko) 2023-04-06
JP2023540849A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
CN108785265B (zh) 杂环化合物和其用途
US10357465B2 (en) Eutectic formulations of cyclobenzaprine hydrochloride
TW201519889A (zh) 環苯扎林鹽酸鹽及阿密替林鹽酸鹽之共晶調配物
JP2012500800A (ja) 神経因性疼痛の治療法
US20250099445A1 (en) Methods of treatment of tuberous sclerosis complex
JP2020528881A (ja) フェノラミンｇ型結晶、その製造方法並びにその組成物及び用途
TW202220649A (zh) 三叉神經痛之治療方法
JPWO2006064754A1 (ja) 睡眠障害予防治療剤
WO2024118936A1 (en) 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies
OA21124A (en) Methods of treatment of trigeminal neuralgia.
JP5591828B2 (ja) 非ステロイド系抗炎症薬およびコルチコシド誘導体を含有する有効成分の新規な組み合わせ
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
TWI659739B (zh) 便秘症之預防或治療藥
AU2024271976A1 (en) Method for administering modulator targeting s1pr1 and s1pr4
KR20100086332A (ko) 비-스테로이드성 항염증제 및 콜히코사이드 유도체를 함유하는 활성 성분들의 신규 조합물
HK40047283B (en) Eutectic formulations of cyclobenzaprine hydrochloride